v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Series B Non-Voting Convertible Preferred Stock
Series C Non-Voting Convertible Preferred Stock
Preferred Stock
Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Preferred Stock
Series C Non-Voting Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2024       161            
Beginning balance (in shares) at Dec. 31, 2024             1,316,989      
Beginning balance at Dec. 31, 2024 $ 15,831     $ 1,360       $ 291,898 $ (277,524) $ 97
Stock-based compensation expense 351             351    
Conversion of Series A preferred shares to Common Stock (in shares)       (2)     (2,201)      
Conversion of Series A preferred shares to Common Stock       $ (19)       19    
Issuance of common stock in connection with vesting of restricted stock units (in shares)             5,370      
Issuance of common stock in connection with vesting of restricted stock units 29             29    
Other comprehensive income (loss), net 712                 712
Net Income (Loss) (5,970)               (5,970)  
Ending balance (in shares) at Jun. 30, 2025       159            
Ending balance (in shares) at Jun. 30, 2025             1,324,560      
Ending balance at Jun. 30, 2025 10,953     $ 1,341       292,297 (283,494) 809
Beginning balance (in shares) at Mar. 31, 2025       161            
Beginning balance (in shares) at Mar. 31, 2025             1,322,359      
Beginning balance at Mar. 31, 2025 13,709     $ 1,360       292,106 (280,057) 300
Stock-based compensation expense 172             172    
Conversion of Series A preferred shares to Common Stock (in shares)       (2)     (2,201)      
Conversion of Series A preferred shares to Common Stock       $ (19)       19    
Other comprehensive income (loss), net 509                 509
Net Income (Loss) (3,437)               (3,437)  
Ending balance (in shares) at Jun. 30, 2025       159            
Ending balance (in shares) at Jun. 30, 2025             1,324,560      
Ending balance at Jun. 30, 2025 10,953     $ 1,341       292,297 (283,494) 809
Beginning balance $ 1,341                  
Beginning balance (in shares) at Dec. 31, 2025 159     159            
Beginning balance (in shares) at Dec. 31, 2025         16,366 43,882 1,597,321      
Beginning balance at Dec. 31, 2025 $ 240,380     $ 1,341 $ 117,621 $ 297,291   310,688 (487,363) 802
Stock-based compensation expense 9,278             9,278    
Conversion of Series C Preferred Stock issued in connection with the asset acquisition of Damora Therapeutics, Inc (in shares)           (2,364) 2,364,000      
Conversion of Series C Preferred Stock issued in connection with the asset acquisition of Damora Therapeutics, Inc           $ (16,990)   16,990    
Stockholder approval of the issuance of common stock upon conversion of Series C non-voting convertible preferred stock (in shares)           (39,641) 39,641,000      
Stockholder approval of the issuance of common stock upon conversion of Series C non-voting convertible preferred stock           $ (266,811) $ 1 266,810    
Issuance of common stock in connection with offering, net of issuance costs of $20,753 (in shares)             16,644,737      
Issuance of common stock in connection with offering, net of issuance costs of $20,753 $ 295,497             295,497    
Conversion of Series A preferred shares to Common Stock (in shares)       (159)     (158,361)      
Conversion of Series A preferred shares to Common Stock       $ (1,341)       1,341    
Forfeiture of shares (in shares)           (155)        
Forfeiture of shares           $ (1,114) $ 9,638 1,114    
Issuance of common stock in connection with vesting of restricted stock units (in shares)             6,018      
Exercise of stock options (in shares) 92,402           92,402      
Exercise of stock options $ 649             649    
Other comprehensive income (loss), net (70)                 (70)
Proceeds from At-the-Market facility (in shares)             1,240,400      
Proceeds from At-the-Market facility 29,282             29,282    
Net Income (Loss) $ (58,957) $ (12,893) $ (8,683)           (58,957)  
Ending balance (in shares) at Jun. 30, 2026 0                  
Ending balance at Jun. 30, 2026 $ 0                  
Ending balance (in shares) at Jun. 30, 2026         16,366 1,722 61,734,601      
Ending balance at Jun. 30, 2026 516,059       $ 117,621 $ 12,376 $ 1 931,649 (546,320) 732
Beginning balance (in shares) at Mar. 31, 2026       159            
Beginning balance (in shares) at Mar. 31, 2026         16,366 1,877 60,303,212      
Beginning balance at Mar. 31, 2026 511,603     $ 1,341 $ 117,621 $ 13,490 $ 1 893,542 (515,146) 754
Stock-based compensation expense 6,144             6,144    
Conversion of Series A preferred shares to Common Stock (in shares)       (159)     (158,361)      
Conversion of Series A preferred shares to Common Stock       $ (1,341)       1,341    
Forfeiture of shares (in shares)           (155)        
Forfeiture of shares           $ (1,114)   1,114    
Issuance of common stock in connection with vesting of restricted stock units (in shares)             726      
Exercise of stock options (in shares)             31,902      
Exercise of stock options 226             226    
Other comprehensive income (loss), net (22)                 (22)
Proceeds from At-the-Market facility (in shares)             1,240,400      
Proceeds from At-the-Market facility 29,282             29,282    
Net Income (Loss) $ (31,174) $ (6,441) $ (678)           (31,174)  
Ending balance (in shares) at Jun. 30, 2026 0                  
Ending balance at Jun. 30, 2026 $ 0                  
Ending balance (in shares) at Jun. 30, 2026         16,366 1,722 61,734,601      
Ending balance at Jun. 30, 2026 516,059       $ 117,621 $ 12,376 $ 1 $ 931,649 $ (546,320) $ 732
Beginning balance $ 0